...
首页> 外文期刊>The American Journal of Cardiology >Heterogeneity in Statin Indications Within the 2013 American College of Cardiology/American Heart Association Guidelines
【24h】

Heterogeneity in Statin Indications Within the 2013 American College of Cardiology/American Heart Association Guidelines

机译:2013年美国心脏病学会/美国心脏协会指南中他汀类药物适应证的异质性

获取原文
获取原文并翻译 | 示例

摘要

A standard ("core") implementation of American College of Cardiology/American Heart Association 2013 lipid guidelines (based on 10-year risk) dramatically increases the statin-eligible population in older Americans, raising controversy in the cardiovascular community. The guidelines also endorse a more "comprehensive" risk approach based in part on lifetime risk. The impact of this broader approach on statin eligibility remains unclear. We studied the impact of 2 different implementations of the new guidelines ("core" and "comprehensive") using the National Health and Nutrition Examination Survey. Although "core" guidelines led to 72.0 million subjects qualifying for statin therapy, the broader "comprehensive" application led to nearly a twofold greater estimate for statin-eligible subjects (121.2 million), with the greatest impact among those aged 21 to 45 years. Subjects indicated for statin therapy under comprehensive guidelines had a greater burden of cardiovascular risk factors and a higher lifetime risk of cardiovascular disease than those not indicated for statins. In particular, men aged 21 to 45 years had a 3.13-fold increased odds of being eligible for statin therapy only under the "comprehensive" guidelines (vs standard "core" guidelines; 95% confidence interval 2.82 to 3.47, p <0.0001). There were no racial differences. In conclusion, the "comprehensive" approach to statin eligibility espoused by the American College of Cardiology/American Heart Association 2013 guidelines would increase the statin-eligible population to over 120 million Americans, particularly targeting younger men with high-risk factor burden. (C) 2015 Elsevier Inc. All rights reserved.
机译:美国心脏病学会/美国心脏协会2013年脂质指南的标准(“核心”实施)(基于10年风险)大大增加了美国老年人的他汀类药物合格人群,在心血管领域引起了争议。该指南还认可了部分基于生命周期风险的更“全面”的风险方法。尚不清楚这种更广泛的方法对他汀类药物资格的影响。我们使用国家健康和营养检查调查研究了新准则的两种不同实施方式(“核心”和“综合”)的影响。尽管“核心”指南使7200万受试者具有他汀类药物治疗的资格,但更广泛的“全面”应用导致对符合他汀类药物的受试者(1.212亿)的估计数增加了将近两倍,在21岁至45岁的受试者中影响最大。与未指示他汀类药物治疗的受试者相比,根据综合指南指示为他汀类药物治疗的受试者具有更大的心血管危险因素负担和更高的终生心血管疾病风险。尤其是,年龄在21至45岁之间的男性仅根据“综合”指南(与标准“核心”指南; 95%置信区间为2.82至3.47,p <0.0001),才有资格获得他汀类药物治疗的机率增加了3.13倍。没有种族差异。总之,美国心脏病学会/美国心脏协会2013年指南所倡导的“全面”的他汀类药物入选方法将使符合他汀类药物的人群增加到1.2亿以上,特别是针对高风险因素负担的年轻男性。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号